Elevance Health (ELV) delivered a third-quarter beat that is large on paper and more modest underneath. Adjusted EPS of $6.99 topped the $4.66 consensus by 41.2% and cleared the $4.95 Earnings Whisper number. Earnings grew 15.9% year over year, a sharp turn from the nine-month trend, where adjusted EPS was up just 0.7%. Revenue of $51.429 billion beat the $48.53 billion consensus by 6.0% and grew 1.4%. Management raised full-year adjusted EPS guidance to at least $29.00 from $27.00, the third consecutive increase. The central tension is that most of the beat came from below the operating line, while the more durable signal sits in a smaller number: the 2026 earnings baseline.

The quality of the beat deserves scrutiny. The company itself flagged a $1.85-per-share net non-operating benefit, and the call put operating outperformance at only about $0.50. Net investment income jumped 65.9% to $1.04 billion, and that line accounts for much of the gap between total revenue growth of 1.4% and operating revenue growth of just 0.7%. Adjusted operating gain was essentially flat at $1.34 billion, and the adjusted operating margin held at 2.7%. Within the segments:

• **Health Benefits:** operating gain fell 27.5% to $436 million, and margin compressed to 1.0% from 1.4%. Management attributed the decline to targeted one-time investments, which pushed the adjusted operating expense ratio up 90 basis points to 11.3%.
• **Carelon:** carried the operating story. CarelonRx operating gain rose 10.8% at a 5.3% margin, and Carelon Services operating gain climbed 33.3%.
• **GAAP earnings:** GAAP EPS of $6.27 rose 17.9%. The year-to-date GAAP figure still reflects the $935 million accrual tied to the CMS Medicare Advantage risk-adjustment notice.

The medical cost picture is the more encouraging part of the release. The benefit expense ratio improved 70 basis points to 90.6%, driven by better Medicare Advantage and Individual ACA performance. Days in claims payable rose 3.5 days to 44.9, which suggests reserves were not drained to manufacture the result. Cash generation was strong: nine-month operating cash flow reached $7.5 billion versus $4.2 billion a year earlier, and full-year guidance rose to at least $6.5 billion.

The call preserved a credible improvement story. The most important number was the earnings baseline, which excludes non-recurring investment income and one-time investments. It rose to at least $26.75 from $26.00, the base on which management reiterated at least 12% adjusted EPS growth in 2027. Several business lines showed progress:

• **Medicaid:** tracking slightly ahead of its roughly -1.75% margin guide on July 1 rate actions. Management described the business as moving from stabilization to improvement.
• **Medicare Advantage:** on track for at least a 2% margin, with about half of members in 4-plus-star plans for 2027.
• **Individual ACA:** year-end membership guidance rose to at least 1.2 million from 1.0 million.
• **Commercial:** management cited jumbo employers returning for January 2027, a commercial pipeline above one million members, and more than $300 million of anticipated savings from the Elevate platform.

Bears have legitimate ammunition. Medical membership fell by 487,000 year over year, with Medicare Advantage down 15.5%, Medicaid down 4.9% and Employer Group risk down 6.9%. Medicaid cost trend remains elevated, and rates have not fully caught up. H.R.1 work requirements introduce acuity uncertainty for 2027. The Medicaid upside is only "slightly ahead" despite earlier constructive rate commentary. Management also expects a discrete tax item in the fourth quarter, continuing IDR pressure in commercial, and an ACA risk pool that needs more than one renewal cycle to normalize. Prior non-operating gains have also been reinvested rather than dropped to the bottom line, which limits how much of this quarter's windfall investors should capitalize.

The market setup is more complicated than the surprise implies, because the stock had already moved. Shares closed at $440.18 entering the report, up 12.1% since the opening after the July release. That close sat just below a $440.67 inter-earnings and 52-week high set the same day, 21.3% above the late-July low, and 19% above the 200-day moving average. Investor sentiment improved only modestly, moving from slightly negative (-0.04) to roughly neutral (0.01). The Earnings Whispers trend signals are mostly positive, with price, momentum and sequential growth all pointing upward. The result is a recovery that has been priced in part but not embraced with enthusiasm.

The bottom line is that Elevance's headline beat overstates the operating improvement, since investment income did much of the heavy lifting. Still, the higher 2026 baseline, better medical cost ratio, Medicaid inflection and Carelon strength give the 2027 growth target a firmer foundation than it had a quarter ago. With shares at their highs and sentiment only neutral, the next test is whether membership stabilizes and Medicaid margins improve beyond "slightly ahead" of guidance.